Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
January 7, 2008
- NHI Drug Prices to Receive 5.2% Cut in April 2008
January 7, 2008
- Concurrent Use of Unapproved Drugs with Insurance-Covered Healthcare to Be Allowed
January 7, 2008
- Mean Gap of 6.9% Found between Market Prices and NHI Prices
January 7, 2008
- Banyu Commemorates 1st Anniversary of Preminent Launching
January 7, 2008
- Korosho, MOF Agree on 0.38% Increase in Medical Fees
January 7, 2008
- GENERICS NEWS IN BRIEF
January 7, 2008
- Gov't Decides to Increase Medical Fees 0.38%
January 7, 2008
- Kyowa Pharm. Ind. to Launch 20 New Products Every Year
January 7, 2008
- BUSINESS NEWS IN BRIEF
January 7, 2008
- SSP Revises Business Forecast Upward
January 7, 2008
- NEW PRODUCTS
January 7, 2008
- Taisho to Launch RiUP Plus
January 7, 2008
- GSK Launches 1st Anticancer Drug Under New Specialist MR System
January 7, 2008
- New OTC Drug Marketing System to Create New Market: Mr Matsumoto
January 7, 2008
- Eisai to Market Stronger Neo Minophagen C in Japan, Euro-Asia Markets
January 7, 2008
- Isoconazole, Emedastine to Be Switched to OTC
January 7, 2008
- AstraZeneca to Revise Invoice Prices as Market Conditions Change
January 7, 2008
- R&D NEWS IN BRIEF
January 7, 2008
- aRigen Licenses ARB-CF0223 to Axentis
January 7, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…